Impact of Gene Polymorphism on Pharmacokinetics and Pharmaco-dynamics of Calcium Channel Blockers: A Narrative Review

IF 0.7 Q4 PHARMACOLOGY & PHARMACY

INDONESIAN JOURNAL OF PHARMACY Pub Date : 2023-09-04 DOI:10.22146/ijp.5283

Sarah Puspita Atmaja, Dwi Aris Agung Nugrahaningsih, Ellsya Angeline Rawar, None Ani Kristiyani, Ahmad Hamim Sadewa, Dita Maria Virginia

{"title":"Impact of Gene Polymorphism on Pharmacokinetics and Pharmaco-dynamics of Calcium Channel Blockers: A Narrative Review","authors":"Sarah Puspita Atmaja, Dwi Aris Agung Nugrahaningsih, Ellsya Angeline Rawar, None Ani Kristiyani, Ahmad Hamim Sadewa, Dita Maria Virginia","doi":"10.22146/ijp.5283","DOIUrl":null,"url":null,"abstract":"A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. This study will carry out more research to ascertain which SNPs have the most influence on the effectiveness of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms \"calcium channel blocker,\" \"efficacy,\" \"blood pressure response,\" \"pharmacokinetic,\" and \"polymorphism\" OR \"genetic\" OR \"genomic\" to find pertinent articles. When prescription antihypertensive medications, particularly calcium channel blockers, it is important to take into account certain gene variants for example CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T , RyR3 gene rs877087 because of their considerable effects.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.5283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. This study will carry out more research to ascertain which SNPs have the most influence on the effectiveness of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms "calcium channel blocker," "efficacy," "blood pressure response," "pharmacokinetic," and "polymorphism" OR "genetic" OR "genomic" to find pertinent articles. When prescription antihypertensive medications, particularly calcium channel blockers, it is important to take into account certain gene variants for example CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T , RyR3 gene rs877087 because of their considerable effects.

查看原文本刊更多论文

基因多态性对钙通道阻滞剂药代动力学和药效学影响的研究综述

一类被称为钙通道阻滞剂(CCBs)的药物被用于治疗高血压、心绞痛和心律失常。这类药物有两个子类:二氢吡啶类和非二氢吡啶类。CYP3A5*3、AGTR1 rs275653、ABCB1 (MDR1) rs1045642和POR*28 A503V的研究都研究了snp对CCBs的影响。本研究将开展更多的研究，以确定哪些snp对CCBs的有效性影响最大。本文的叙事评论来源多样。我们使用“钙通道阻滞剂”、“功效”、“血压反应”、“药代动力学”和“多态性”或“遗传”或“基因组”等术语在Pubmed、ScienceDirect和Google Scholar中进行搜索，以找到相关文章。在处方降压药物，特别是钙通道阻滞剂时，重要的是要考虑某些基因变异，如CYP3A5*3/*3、CYP3A4 *1G/*1G、MDR1 C3435T、RyR3基因rs877087，因为它们的作用相当大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

INDONESIAN JOURNAL OF PHARMACY PHARMACOLOGY & PHARMACY-

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.